NET should not only be used to allow surgery or to improve BCS rates in patients not eligible for NCT, but also as a research tool for the search for endocrine sensitivity biomarkers and targeted therapies, and for prognostic information in ER+/HER2- BC. Here, ERBB2 is linked to breast cancer.